B. Riley raised the firm’s price target on Oncology Institute (TOI) to $8 from $6 and keeps a Buy rating on the shares. Oncology Institute delivered its first profitable quarter as a public company in Q4 and management reiterated 2026 guidance of $630M-$650M revenue, highlighting near-doubling of capitated revenue from Florida contract ramp-ups and new payer wins, signaling an inflection point for its value-based care model, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOI:
- Undervalued Oncology Institute Poised for Upside as Improving Fundamentals and Delegated Contracts Support Buy Rating and $5 Target
- TOI Earnings this Week: How Will it Perform?
- Oncology Institute Adds Independent Director to Board
- Oncology Institute appoints Kim Tzoumakas to board of directors
- Oncology Institute management to meet with BTIG